Next-generation vaccine platform takes aim at drug-resistant gonorrhoea

This article is in partnership with:

Anita Gashi,

Chief Executive Officer, AdJane

Maria Grazia Pau,

Chief Scientific Officer, AdJane

Peter van der Ley,

Scientific Advisor, AdJane

A biotech company has built a scalable, clinical-stage vaccine platform on a proven technology. Its gonorrhoea vaccine aims to prevent infection and combat antimicrobial resistance (AMR).


The AMR threat from the common sexually transmitted infection gonorrhoea is serious and growing, stresses Gashi.

Resistance to gonorrhoea treatments increases

The World Health Organization reports that resistance to the recommended first-line treatment for gonorrhoea rose from 0.8% in 2022 to 5% in 2024.1 “That leaves clinicians with fewer options,” says Gashi. “Vaccines are a promising way to tackle AMR, and we have a platform built on decades of public health research and Phase 1 clinical data showing it is safe and immunogenic.”

If adolescents can be vaccinated before exposure, they won’t need antibiotics. “Fewer people on antibiotics means less pressure driving resistance,” says Pau.

Closing the vaccine gap

Several vaccines tested against gonorrhoea were designed for a related bacterium, meningococcus B. These have demonstrated partial protection in observational studies but have delivered no protection in a randomised controlled trial.

AdJane is developing a gonorrhoea-specific vaccine on its proprietary native outer membrane vesicle (nOMV) platform derived from Neisseria meningitidis and genetically modified to express gonococcal antigens. Unlike repurposed meningococcal vaccines, this candidate is designed as a single-component, self-adjuvanting vaccine.

Vaccines are a promising way to tackle AMR, and we have a platform built on decades of public health research

“Outer membrane vesicles are naturally released by Gram-negative bacteria and carry the same surface components as the bacterium itself, so the immune system readily recognises them,” explains van der Ley. “Historically, their broader use was limited by the challenge of producing at scale.”

AdJane has addressed this through the engineering of its nOMV platform and manufacturing process. Genetic engineering of the bacteria detoxifies the vesicles by reducing the inflammatory effect of endotoxin, making them safer and increasing vesicle production to support production at the scale needed for broad vaccination programmes.

A Phase 1 trial of an intranasal vaccine on the platform showed it to be safe and to induce mucosal and systemic immune responses. The platform can be applied across bacterial and viral pathogens. “It has broad applicability beyond gonorrhoea,” says Gashi. “We are open to working with vaccine developers who have identified antigens for specific diseases and need a clinically tested platform to take them forward. Together, we could bring protection against more diseases to patients faster.”

[1] World Health Organization. More countries report rising levels of drug-resistant gonorrhoea, warns WHO [Internet]. 2025 Nov 19. Available from: https://www.who.int/news/item/19-11-2025-more-countries-report-rising-levels-of-drug-resistant-gonorrhoea–warns-who
[2] van der Pol L, Stork M, van der Ley P. Outer membrane vesicles as platform vaccine technology. Biotechnol J. 2015;10:1689-706.
[3] van der Ley P, Steeghs L, Hamstra HJ, et al. Modification of lipid A biosynthesis in Neisseria meningitidis lpxL mutants: influence on lipopolysaccharide structure, toxicity, and adjuvant activity. Infect Immun. 2001;69:5981-90.

More from AMR & Infectious Diseases